8 months ago
FOLD
AnalystsTazeen AhmadTazeen Ahmad's Stock Forecasts
AnalystsTazeen Ahmad
Analyst Ranking
Bottom 6%
#4656 out of 4922 analysts
Average Return
-2.89%
Win Rate
46%68 out of 148
Risk vs Reward
Poor
Good
Tazeen Ahmad's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunomedics IncIMMU | +339.08% | $20.01 | $87.86 | 2019-12-19 - 2020-10-22 | Strong Buy |
Argenx SeARGX | +133.81% | $157.46 | $368.16 | 2020-02-09 - 2021-02-10 | Strong Buy |
Avexis IncAVXS | +127.40% | $95.79 | $217.83 | 2017-11-09 - 2018-05-15 | Strong Buy |
Ascendis Pharma AASND | +109.30% | $71.43 | $149.50 | 2023-04-03 - 2024-04-03 | Strong Buy |
Acadia Pharmaceuticals IncACAD | +100.00% | $20.24 | $40.48 | 2018-10-09 - 2019-10-10 | Strong Buy |
Tazeen Ahmad Analyst Color
Get additional color on Tazeen Ahmad's coverage of popular stocks
2 years ago
RYTM
2 years ago
APLS
2 years ago
FDMT
2 years ago
SRPT
2 years ago
GRTX
3 years ago
PRTA
3 years ago
ASND
Tazeen Ahmad's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Sarepta Therapeutics IncSRPT | 22 | Hold | $28.00 | +63.65% | Downgrades | 14 days ago |
Ascendis Pharma AASND | 9 | Strong Buy | $216.00 | +25.42% | Maintains | 21 days ago |
Acadia Pharmaceuticals IncACAD | 10 | Hold | $23.00 | +3.98% | Maintains | 25 days ago |
Prothena Corp Public Ltd CoPRTA | 6 | Sell | $4.00 | -34.21% | Downgrades | a month ago |
Sutro Biopharma IncSTRO | 3 | Sell | $0.80 | +8.99% | Maintains | a month ago |
Denali Therapeutics IncDNLI | 3 | Strong Buy | $27.00 | +91.49% | Maintains | a month ago |
Apellis Pharmaceuticals IncAPLS | 7 | Hold | $23.00 | +31.96% | Downgrades | 2 months ago |
Ptc Therapeutics IncPTCT | 12 | Strong Buy | $68.00 | +36.44% | Upgrades | 2 months ago |
Rhythm Pharmaceuticals IncRYTM | 8 | Strong Buy | $68.00 | +8.40% | Maintains | 3 months ago |
Alnylam Pharmaceuticals IncALNY | 3 | Strong Buy | $325.00 | +0.67% | Maintains | 3 months ago |
Arvinas IncARVN | 2 | Strong Buy | $28.00 | +271.35% | Maintains | 4 months ago |
Merus NvMRUS | 5 | Strong Buy | $70.00 | +32.10% | Maintains | 4 months ago |
4d Molecular Therapeutics IncFDMT | 4 | Strong Buy | $40.00 | +941.67% | Maintains | 4 months ago |
Neurocrine Biosciences IncNBIX | 2 | Strong Buy | $179.00 | +42.72% | Maintains | 5 months ago |
Kalvista Pharmaceuticals IncKALV | 1 | Strong Buy | $22.00 | +92.81% | Initiates Coverage On | 6 months ago |
Pepgen IncPEPG | 3 | Sell | $3.00 | +160.87% | Downgrades | 6 months ago |
Incyte CorpINCY | 5 | Strong Buy | $90.00 | +31.64% | Upgrades | 8 months ago |
Amicus Therapeutics IncFOLD | 5 | Strong Buy | $15.00 | +152.95% | Maintains | 8 months ago |
Sage Therapeutics IncSAGE | 13 | Sell | $6.00 | -34.43% | Maintains | 9 months ago |
Biontech SeBNTX | 6 | Strong Buy | $150.00 | +40.55% | Maintains | 9 months ago |
Fulcrum Therapeutics IncFULC | 4 | Sell | $2.00 | -71.83% | Downgrades | 10 months ago |
Argenx SeARGX | 3 | Strong Buy | $607.00 | N/A | Reiterates | a year ago |
Ultragenyx Pharmaceutical IncRARE | 4 | Strong Buy | $76.00 | N/A | Maintains | a year ago |
Inozyme Pharma IncINZY | 2 | Strong Buy | $14.00 | N/A | Maintains | a year ago |
Annexon IncANNX | 4 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Fate Therapeutics IncFATE | 2 | Sell | $6.00 | N/A | Maintains | a year ago |
Ocular Therapeutix IncOCUL | 1 | Strong Buy | $15.00 | N/A | Initiates Coverage On | a year ago |
Cyteir Therapeutics IncCYTT | 2 | Sell | $3.00 | N/A | Downgrades | a year ago |
Achilles Therapeutics PLCACHL | 1 | Sell | $0.50 | N/A | Downgrades | 2 years ago |
Pharvaris NvPHVS | 3 | Sell | $11.00 | N/A | Maintains | 2 years ago |
Cerevel Therapeutics Holdings IncCERE | 2 | Hold | $31.00 | N/A | Downgrades | 2 years ago |
Biocryst Pharmaceuticals IncBCRX | 2 | Strong Buy | $10.00 | N/A | Upgrades | 2 years ago |
Adc Therapeutics SaADCT | 2 | Sell | $2.00 | N/A | Downgrades | 2 years ago |
Galera Therapeutics IncGRTX | 2 | Strong Buy | $7.00 | N/A | Upgrades | 2 years ago |
Sqz Biotechnologies CoSQZB | 2 | Sell | $2.00 | N/A | Downgrades | 3 years ago |
Prelude Therapeutics IncPRLD | 4 | Sell | $6.00 | N/A | Downgrades | 3 years ago |
Surrozen IncSRZN | 3 | Sell | $15.00 | N/A | Downgrades | 3 years ago |
Praxis Precision Medicines IncPRAX | 2 | Hold | $60.00 | N/A | Downgrades | 3 years ago |
Molecular Templates IncMTEM | 2 | Sell | $22.50 | N/A | Downgrades | 3 years ago |
Pyxis Oncology IncPYXS | 1 | Hold | $16.00 | N/A | Initiates Coverage On | 4 years ago |
Quince Therapeutics IncQNCX | 1 | Sell | N/A | N/A | Downgrades | 4 years ago |
Akouos IncAKUS | 2 | Hold | $20.00 | N/A | Downgrades | 4 years ago |
Orphazyme AORPHY | 1 | Sell | $5.00 | N/A | Downgrades | 4 years ago |
89bio IncETNB | 1 | Strong Buy | $43.00 | N/A | Upgrades | 5 years ago |
Clovis Oncology IncCLVSQ | 1 | Sell | $6.00 | N/A | Downgrades | 5 years ago |
Immunomedics IncIMMU | 1 | Strong Buy | $26.00 | N/A | Initiates Coverage On | 6 years ago |
Dbv Technologies SaDBVT | 1 | Strong Buy | $300.00 | N/A | Maintains | 7 years ago |
Tesaro IncTSRO | 4 | Hold | $39.00 | N/A | Maintains | 7 years ago |
Spero Therapeutics IncSPRO | 2 | Sell | $9.00 | N/A | Downgrades | 7 years ago |
Pacira Biosciences IncPCRX | 3 | Hold | $48.00 | N/A | Maintains | 7 years ago |
Adamas Pharmaceuticals IncADMS | 2 | Hold | $25.00 | N/A | Downgrades | 7 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Strong Buy | $200.00 | N/A | Maintains | 7 years ago |
Ptc IncPTC | 3 | Hold | $102.00 | N/A | Maintains | 7 years ago |
Seagen IncSGEN | 1 | Hold | $68.00 | N/A | Maintains | 7 years ago |
Avexis IncAVXS | 1 | Strong Buy | $112.00 | N/A | Maintains | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.